Other News To Note

SomaGenics Inc., of Santa Cruz, Calif., presented data on the efficacy of RNA interference (RNAi) therapeutics against hepatitis C virus (HCV) based on the company's sshRNA platform. SomaGenics' synthetic sshRNAs, formulated with lipid nanoparticles (LNP) from collaborator Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, demonstrated reduced circulating HCV load by more than two orders of magnitude.